METUPUK is delighted that the drug combination capivasertib plus fulvestrant has been recommended by NICE for patients with oestrogen receptor positive metastatic breast cancer who:
· have progressed on hormonal treatment
· have one or more PIK3CA, AKT1 or PTEN gene alterations
Capivasertib with fulvestrant is a promising drug combination which can double the length of time patients have before cancer comes back. Capivasertib is also the first drug available to inhibit AKT, a molecule which drives cancer cell growth.
The Institute of Cancer Research in London had a pivotal role in the development of capivasertib. This began with unravelling the role that AKT has in cancer biology, and then working with a UK bioscience company to develop prototype drugs which could inhibit AKT. These drugs were then refined leading to the creation of the final drug capivasertib which has now been made available to patients. The process took around 25 years, beginning in the year 2000.
It is always encouraging to see cancer research leading to drugs which are available to patients. However, capivasertib with fulvestrant is not a cure for metastatic breast cancer. Until the statistic of 31 women dying every day in the UK from metastatic breast cancer is no more, we at METUPUK will carry on advocating for patients.
We urge the SMC to evaluate capivasertib with fulvestrant without delay. In Scotland there are no drugs available which target PIK3CA, AKT1 or PTEN gene alterations. Postcode lotteries are divisive and distressing for patients.
Improved drug access allows us to stay
#BusyLivingWithMets and increase our survival outcomes.
We Demand Change.
#drugapproval #DarkerPink #BusyLivingWithMets #IAmThe31 #DyingForACure #MetastaticBreastCancer #severitymodifier #SecondaryBreastCancer #Stage4NeedsMore #StageIVNeedsMore #AdvancedBreastCancer